Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
Bullboard Posts
User Avatar Image
(2)
•••
Comment by Trappist1on May 27, 2013 5:27am
215 Views
Post# 21444589

RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE

RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE

The PM industry is evolving after underperforming spot Gold for years with a reason. Big gold miners have been growing via external growth and diluting their paper while junior miners cant raise the cash to fund their projects. A lot of the high level CEO's have been ousted, CEO's at smaller companies who cant get send away are being rewarded with their stock plummeting ...

 

To comment on this discussion. cash costs used to be the industry benchmark, but this is evolving. Look at the gold survey of GFMS 2013, "ALL-IN SUSTAINABLE COSTS" is the way forward. And this is a good thing. Mining gold at direct cash costs is one thing, taking into account development, corporate and interest rates costs is very much needed.

 

I am very pessimistic about miners without operational basis. I do not think they will make it, not even with a gold price going up again. eg Fridays comment of SLW: "Up to 50% of juniors could disappear if financing doesn't improve" - Haytham Hodaly SLW

 

please be kind to each other in this forum

 

Maybe we cant discuss Brigus Gold in more detail?

1. How do you see the impact of the mill stoppage on Q2 figures ?

2. Is postponing Grey Fox far into 2014 a good or a bad thing?

 

thanks,

Trappist

 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities